News & Updates  

Estimated reading time: 4 minutes

Mass General Brigham Launches AIwithCare to Transform Clinical Trials

  • AIwithCare aims to revolutionize patient matching in clinical trials using advanced AI technology.
  • The RECTIFIER tool speeds up eligibility screening and has doubled enrollment rates in studies.
  • Leadership includes CEO A.J. Blood, MD, and President Sandy Aronson, focusing on trial diversity.
  • This initiative highlights a significant trend towards integrating AI in healthcare for better patient outcomes.
  • AIwithCare’s launch represents a substantial transformation in clinical trial processes and accessibility.

Table of Contents

AIwithCare: A New Dawn in Clinical Trials

In a game-changing announcement in the world of artificial intelligence, Mass General Brigham has launched a new AI spinout, AIwithCare, aimed at revolutionizing patient matching for clinical trials. This innovative company was unveiled on December 12, 2025, and has been developed to expedite the eligibility screening process using the advanced RECTIFIER tool, a marvel of retrieval-augmented generation (RAG) AI technology.

AIwithCare leverages cutting-edge AI to analyze electronic health records (EHR), both structured and unstructured, delivering faster and more accurate eligibility screenings than traditional manual methods. This transformative approach is set to significantly impact clinical trials, which often face substantial delays due to inefficient patient recruitment processes. It addresses one of the fundamental bottlenecks in clinical research by reducing eligibility screening costs, which account for approximately one-third of total trial expenses.

According to Chief Innovation Officer Chris Coburn, the implementation of AIwithCare not only saves money but also enhances trial diversity and efficiency. This is particularly crucial as the clinical research landscape increasingly demands diverse participant enrollment to ensure safety and efficacy across demographics.

The RECTIFIER tool has already demonstrated remarkable success, doubling enrollment rates in clinical studies, including a notable heart failure trial published in the Journal of the American Medical Association (JAMA) in February 2025. Its applications extend beyond clinical trials into various medical fields such as cardiology, oncology, gastroenterology, neurology, and psychiatry, offering potential improvements in safety, quality, and operational efficiency.

Leadership and Future Directions

AIwithCare is led by an experienced team comprising CEO A.J. Blood, MD, and President Sandy Aronson. With a robust focus on commercializing the RECTIFIER tool for other health systems, they aim to set a new standard for patient involvement in clinical trials. This initiative not only promises a faster route from clinical research to market but also aligns with the broader goals of healthcare providers to diversify trial populations and enhance treatment accessibility for various demographic segments.

The launch of AIwithCare is a significant milestone in the integration of AI technology within the healthcare sector, showcasing the potential to transform traditional practices. It represents a broader trend in the industry where technology and medical expertise converge to create solutions that address longstanding challenges.

The Broader Impact of AI in Healthcare

The emergence of AIwithCare highlights the growing influence of artificial intelligence across various sectors, notably healthcare. This development resonates with the ongoing trend of utilizing advanced technologies to streamline operations and improve patient outcomes. The healthcare industry is witnessing an influx of AI solutions tailored to enhance diagnostic accuracy, personalize treatment plans, and make administrative processes more efficient.

As AI continues to evolve, the opportunities for monetizing these innovations are expanding. Startups like AIwithCare exemplify how investment in AI not only serves a vital function in improving healthcare delivery but also represents a lucrative market for investors and entrepreneurs alike. The potential applications of RAG AI and similar technologies can be broad-reaching, leading to new business models that prioritize patient care while also achieving substantial returns.

In conclusion, the launch of AIwithCare represents a pivotal moment in the AI and healthcare landscape. By enhancing clinical trial processes and focusing on patient inclusivity, this new company stands to revolutionize the way clinical research is conducted. As we move into 2026, it is exhilarating to think about the ongoing innovations in AI and their transformative potential in the healthcare field and beyond.

FAQ Section

What is AIwithCare?
AIwithCare is a new AI spinout from Mass General Brigham that aims to enhance patient matching in clinical trials through advanced eligibility screening.

How does the RECTIFIER tool work?
The RECTIFIER tool analyzes electronic health records to deliver faster and more accurate screenings compared to traditional methods.

What are the potential benefits of using AIwithCare?
Benefits include reduced costs for eligibility screening, increased trial diversity, and higher enrollment rates in clinical studies.

Who leads AIwithCare?
AIwithCare is led by CEO A.J. Blood, MD, and President Sandy Aronson.

For more details on this groundbreaking news, you can visit the original reports through Becker’s Hospital Review, MedCity News, and the official Mass General Brigham press release.